OTC Naloxone In US Could Limit Access Due To Costs, Comments On Emergent Switch NDA Argue

 
• By Malcolm Spicer
  
The FDA joint advisory committee will meet on 15 February to discuss Emergent BioSolution's proposed OTC switch of NARCAN. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards